Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 133B 202,954B 118B 110B 99.26B 187B 12,546B 189B 1,315B 516B 6,594B 499B 488B 21,013B P/E 2026 *
35x
P/E 2027 * 28.2x
Enterprise Value 127B 194,203B 113B 105B 94.98B 179B 12,005B 181B 1,258B 494B 6,310B 477B 467B 20,107B EV / Sales 2026 *
9.59x
EV / Sales 2027 * 8.61x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
1 day+1.99%
1 week+5.74%
Current month+1.38%
1 month+4.83%
3 months+12.93%
6 months+33.39%
Current year+23.83%
1 week 7,970
Extreme 7970
8,555
1 month 7,710
Extreme 7710
8,555
Current year 6,115
Extreme 6115
8,825
1 year 5,545
Extreme 5545
8,825
3 years 4,815
Extreme 4815
8,825
5 years 4,815
Extreme 4815
8,825
10 years 4,815
Extreme 4815
8,825
Manager TitleAgeSince
Chief Executive Officer 53 2020-03-31
Director of Finance/CFO 57 2019-04-09
Chief Tech/Sci/R&D Officer - 2025-06-30
Director TitleAgeSince
Director/Board Member 66 1997-12-31
Chairman 70 2012-04-30
Director/Board Member 57 2015-06-17
Change 5-day change 1-year change 3-year change Capi.($)
+1.99%+5.74% - - 130B
-1.01%+5.13%+58.93%+117.36% 1,144B
-0.61%+1.52%+34.34%+68.48% 625B
-1.48%+0.47%+23.08%+94.76% 511B
+0.54%+5.69%+39.60%+64.02% 377B
+1.07%+1.70%+71.06%+45.98% 366B
+0.30%+3.44%+21.35%+49.62% 291B
-0.03%+2.55%+1.12%+20.94% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 194B
Average +0.17%+3.80%+35.42%+68.42% 445.32B
Weighted average by Cap. +0.38%+4.17%+40.81%+79.57%

Financials

2026 *2027 *
Net sales 13.27B 20,256B 11.82B 10.95B 9.91B 18.66B 1,252B 18.89B 131B 51.5B 658B 49.78B 48.74B 2,097B 14.56B 22,235B 12.98B 12.02B 10.87B 20.49B 1,374B 20.73B 144B 56.53B 722B 54.64B 53.5B 2,302B
Net income 3.89B 5,939B 3.47B 3.21B 2.9B 5.47B 367B 5.54B 38.48B 15.1B 193B 14.59B 14.29B 615B 4.89B 7,468B 4.36B 4.04B 3.65B 6.88B 462B 6.96B 48.39B 18.99B 243B 18.35B 17.97B 773B
Net Debt -5.73B -8,751B -5.11B -4.73B -4.28B -8.06B -541B -8.16B -56.7B -22.25B -284B -21.5B -21.06B -906B -7.54B -11,516B -6.72B -6.22B -5.63B -10.61B -712B -10.74B -74.62B -29.28B -374B -28.3B -27.71B -1,192B
Projected Income Statement - Annual - Vertex Pharmaceuticals Incorporated
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
26-10-21 ARS 8,470.00 +1.99% 3,281
26-10-20 ARS 8,305.00 +3.36% 11,709
26-10-19 ARS 8,035.00 +0.75% 1,059
26-10-16 ARS 7,975.00 -2.03% 1,240
26-10-15 ARS 8,140.00 +1.62% 1,559
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Vertex Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
524.52USD
Average target price
571.46USD
Spread / Average Target
+8.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vertex Pharmaceuticals Incorporated